4-Aminophenyl 2-Acetamido-2-deoxy-beta-D-glucopyranoside

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Aminophenyl 2-Acetamido-2-deoxy-beta-D-glucopyranoside
• 英文别名: N-[2-(4-aminophenoxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
• 化学式: C₁₄H₂₀N₂O₆
• 分子量: 312.32
• InChiKey: RWZITXGZJXXMRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  134
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• Immunodulating small molecules
  申请人：AyuVis Research, Inc.

  公开号：US11364253B2

  公开（公告）日：2022-06-21

  The present invention includes novel compositions and methods for treating comprising a compound with the Formula I: where n=0-5; X═NH, O, S, CH2; Y=Phenyl, a phenyl group substituted with at least one methyl, a phenyl group substituted with at least one nitro, a phenyl group substituted with at least one nitrogen, a phenyl group substituted with at least one boron, aryl, substituted aryl, heteroaryl, four to six membered cycloalkyl, four to six membered heterocycloalkyl; R═H, C(O)R2, SO2R2; R1═H, C(O)R2, SO2R2; R2=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, NH2, NR3R4, R3, R4=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, three to six membered cycloalkyl and Z═NH, O, S, CH2 or none, wherein the amount of the compound is selected to either inhibit or activate the immune response.

  本发明包括由式 I 化合物组成的新型组合物和治疗方法： 其中n＝0-5；X═NH，O，S，CH2；Y＝苯基，被至少一个甲基取代的苯基，被至少一个硝基取代的苯基，被至少一个氮取代的苯基，芳基，取代的芳基，杂芳基，四至六位环烷基，四至六位杂环烷基；R═H，C(O)R2，SO2R2； R1═H，C(O)R2，SO2R2；R2=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, NH2, NR3R4, R3, R4=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, three to six membered cycloalkyl and Z═NH, O, S, CH2 or none, 其中化合物的量被选择为抑制或激活免疫反应。
• GALACTOSIDES AND THIODIGALACTOSIDES AS INHIBITORS OF PA-IL LECTIN FROM PSEUDOMONAS
  申请人：Magnani John L.

  公开号：US20090176717A1

  公开（公告）日：2009-07-09

  Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.